• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

碳离子放射治疗高危脑膜瘤。

Carbon ion radiation therapy for high-risk meningiomas.

机构信息

Department of Radiation Oncology, University Hospital of Heidelberg, 69120 Heidelberg, Germany.

出版信息

Radiother Oncol. 2010 Apr;95(1):54-9. doi: 10.1016/j.radonc.2009.12.029. Epub 2010 Feb 25.

DOI:10.1016/j.radonc.2009.12.029
PMID:20189258
Abstract

BACKGROUND

We analyzed outcome after a carbon ion boost in combination with precision photon radiation therapy in patients with meningiomas.

PATIENTS AND METHODS

Ten patients with meningiomas were treated with carbon ion RT as part of a Phase I/II trial. Carbon ion RT was conducted in conjunction with fractionated stereotactic RT (FSRT) or intensity-modulated RT (IMRT). Eight patients were treated as primary RT, in 2 patients carbon ion RT was performed as re-irradiation. Carbon ion RT was applied with a median dose of 18 GyE, and photon RT was applied with a median dose of 50.4 Gy. Two patients with a history of former irradiation received 18GyE of carbon ion RT and a reduced dose of photon treatment.

RESULTS

The median follow-up time was 77 months. Five patients died during follow-up, of which four died of tumor progression. In the group treated in the primary situation, actuarial survival rates after RT were 75% and 63% at 5 and 7 years. After re-irradiation, both patients died at 10 and 67 months, respectively. Actuarial local control rates after primary RT were 86% and 72% at 5 and 7 years. Two patients developed tumor recurrence after re-irradiation, 6 and 67 months after treatment.

CONCLUSION

In conclusion, carbon ion radiation shows promising results in patients with atypical or anaplastic meningiomas. Further evaluation in a larger, prospective study in comparison to proton RT or modern photon RT is needed to corroborate these results.

摘要

背景

我们分析了脑膜瘤患者在碳离子增强放疗联合精准光子放疗后的结果。

患者与方法

10 名脑膜瘤患者参与了这项 I/II 期临床试验,接受碳离子放射治疗。碳离子放射治疗与分次立体定向放射治疗(FSRT)或强度调制放射治疗(IMRT)相结合。8 名患者为初治患者,2 名患者为复发性脑膜瘤,行碳离子再放疗。碳离子放射治疗的中位剂量为 18GyE,光子放射治疗的中位剂量为 50.4Gy。2 名有既往放疗史的患者接受了 18GyE 的碳离子放疗和光子治疗的减剂量。

结果

中位随访时间为 77 个月。5 名患者在随访期间死亡,其中 4 名死于肿瘤进展。在初治组中,放疗后 5 年和 7 年的生存率分别为 75%和 63%。在再次放疗后,2 名患者分别在 10 个月和 67 个月死亡。初治后局部控制率分别为 86%和 72%,5 年和 7 年。2 名患者在再次放疗后出现肿瘤复发,分别为 6 个月和 67 个月后。

结论

总之,碳离子放射治疗在非典型或间变性脑膜瘤患者中显示出良好的效果。需要进一步在更大的、前瞻性研究中与质子放疗或现代光子放疗进行比较,以证实这些结果。

相似文献

1
Carbon ion radiation therapy for high-risk meningiomas.碳离子放射治疗高危脑膜瘤。
Radiother Oncol. 2010 Apr;95(1):54-9. doi: 10.1016/j.radonc.2009.12.029. Epub 2010 Feb 25.
2
Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy.非典型性和恶性脑膜瘤患者放疗后的长期预后——单一机构治疗的 85 例患者的临床结果,为早期放疗制定了优化指南。
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):859-64. doi: 10.1016/j.ijrobp.2011.08.010. Epub 2011 Dec 2.
3
Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors.良性或非典型颅内脑膜瘤患者的分次立体定向放射治疗:长期经验及预后因素
Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):809-16. doi: 10.1016/j.ijrobp.2004.07.669.
4
Functional outcome of patients with benign meningioma treated by 3D conformal irradiation with a combination of photons and protons.采用光子与质子联合三维适形放疗治疗的良性脑膜瘤患者的功能预后
Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1412-22. doi: 10.1016/j.ijrobp.2004.12.048.
5
Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.侵袭性脑膜瘤的临床病理特征,强调放射治疗在治疗中的作用。
Strahlenther Onkol. 2006 Nov;182(11):641-6. doi: 10.1007/s00066-006-1555-3.
6
Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma.质子与光子适形放疗联合治疗颅内非典型及恶性脑膜瘤。
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):399-406. doi: 10.1016/j.ijrobp.2008.10.053. Epub 2009 Feb 7.
7
Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques.使用现代放射治疗技术治疗局部晚期腺样囊性癌的策略
Cancer. 2005 Jul 15;104(2):338-44. doi: 10.1002/cncr.21158.
8
Volumetric response of intracranial meningioma after photon or particle irradiation.光子或粒子照射后颅内脑膜瘤的体积反应。
Acta Oncol. 2017 Mar;56(3):431-437. doi: 10.1080/0284186X.2016.1259659. Epub 2016 Dec 2.
9
Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base: long-term experience of a single institution.调强放射治疗颅底复杂形状脑膜瘤:单机构长期经验
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63. doi: 10.1016/j.ijrobp.2006.12.073. Epub 2007 Mar 26.
10
Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and 68Ga-DOTATOC-PET.基于 MRI 和 68Ga-DOTATOC-PET 对脑膜瘤患者靶区勾画的前瞻性评估粒子治疗的早期治疗效果。
Acta Oncol. 2013 Apr;52(3):514-20. doi: 10.3109/0284186X.2013.762996. Epub 2013 Feb 12.

引用本文的文献

1
Adjuvant proton beam therapy in patients with grade 2 meningiomas.2级脑膜瘤患者的辅助质子束治疗
Surg Neurol Int. 2024 Mar 1;15:62. doi: 10.25259/SNI_485_2023. eCollection 2024.
2
Efficacy and toxicity of bimodal radiotherapy in WHO grade 2 meningiomas following subtotal resection with carbon ion boost: Prospective phase 2 MARCIE trial.碳离子局部推量放疗在次全切除术后的 2 级脑膜瘤中的疗效和毒性:前瞻性 2 期 MARCIE 试验。
Neuro Oncol. 2024 Apr 5;26(4):701-712. doi: 10.1093/neuonc/noad244.
3
Particle beam radiotherapy in the treatment of WHO grade 2 and 3 meningiomas: an early experience from Shanghai Proton and Heavy Ion Center.
粒子束放疗治疗世界卫生组织 2 级和 3 级脑膜瘤:上海质子重离子中心的早期经验。
J Neurooncol. 2023 Nov;165(2):241-250. doi: 10.1007/s11060-023-04401-8. Epub 2023 Nov 17.
4
Analysis of recurrence probability following radiotherapy in patients with CNS WHO grade 2 meningioma using integrated molecular-morphologic classification.采用综合分子形态学分类法分析中枢神经系统WHO 2级脑膜瘤患者放疗后的复发概率
Neurooncol Adv. 2023 May 14;5(1):vdad059. doi: 10.1093/noajnl/vdad059. eCollection 2023 Jan-Dec.
5
Efficacy of radiotherapy and stereotactic radiosurgery as adjuvant or salvage treatment in atypical and anaplastic (WHO grade II and III) meningiomas: a systematic review and meta-analysis.放射治疗和立体定向放射外科作为非典型和间变性(世界卫生组织II级和III级)脑膜瘤辅助或挽救性治疗的疗效:一项系统评价和荟萃分析。
Neurosurg Rev. 2023 Mar 17;46(1):71. doi: 10.1007/s10143-023-01969-7.
6
Clinical outcomes of benign brain tumors treated with single fraction LINAC-based stereotactic radiosurgery: Experience of a single institute.基于直线加速器的单次分割立体定向放射外科治疗良性脑肿瘤的临床结果:单机构经验
Tzu Chi Med J. 2022 Jun 27;34(4):462-472. doi: 10.4103/tcmj.tcmj_260_21. eCollection 2022 Oct-Dec.
7
Postoperative radiotherapy for meningiomas - a decision-making analysis.脑膜瘤术后放疗——决策分析。
BMC Cancer. 2022 May 4;22(1):492. doi: 10.1186/s12885-022-09607-z.
8
The Efficacy and Safety of Carbon Ion Radiotherapy for Meningiomas: A Systematic Review and Meta-Analysis.碳离子放疗治疗脑膜瘤的疗效与安全性:一项系统评价与荟萃分析
Front Oncol. 2021 May 25;11:620534. doi: 10.3389/fonc.2021.620534. eCollection 2021.
9
Current experimental therapies for atypical and malignant meningiomas.目前针对非典型性和恶性脑膜瘤的实验性疗法。
J Neurooncol. 2021 Jun;153(2):203-210. doi: 10.1007/s11060-021-03759-x. Epub 2021 May 5.
10
Review of Atypical and Anaplastic Meningiomas: Classification, Molecular Biology, and Management.非典型和间变性脑膜瘤综述:分类、分子生物学与管理
Front Oncol. 2020 Nov 20;10:565582. doi: 10.3389/fonc.2020.565582. eCollection 2020.